Gilead Sciences

Forecast & Rating30 analysts currently cover Gilead Sciences, with about 73.3% giving a positive rating — meaning they expect the stock to rise. The average price target is $157.52, about 21.8% upside from the current price of $129.31. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 82.3% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Gilead Sciences closely still see room for the stock to rise. Data as of Jul 24, 2026; for reference only and not investment advice.